AI assistant
Altimmune, Inc. — Director's Dealing 2024
Feb 6, 2024
33207_dirs_2024-02-05_3adf426f-12eb-41b2-8e62-876e383c048c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2024-02-01
Reporting Person: Harris Matthew Scott (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-01 | Common Stock, par value $0.0001 | M | 6166 | — | Acquired | 49991 | Direct |
| 2024-02-01 | Common Stock, par value $0.0001 | F | 1801 | $9.88 | Disposed | 48190 | Direct |
| 2024-02-02 | Common Stock, par value $0.0001 | M | 7775 | — | Acquired | 55965 | Direct |
| 2024-02-02 | Common Stock, par value $0.0001 | F | 2332 | $9.32 | Disposed | 53633 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-01 | Restricted Stock Units | $ | M | 6166 | Disposed | Common Stock, par value $0.0001 (6166) | Direct | |
| 2024-02-02 | Restricted Stock Units | $ | M | 7775 | Disposed | Common Stock, par value $0.0001 (7775) | Direct |
Footnotes
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F2: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
F3: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
F4: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.